Rational design of immunogenic nanoparticles as a platform to reduce ovarian tumor burden in mice
- 4 October 2025
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 685, 126251
Abstract
No abstract availableKeywords
Funding Information
- Oxnard Foundation (P20GM121176)
- National Institute of General Medical Sciences (P20GM130422-03)
- National Institute of Biomedical Imaging and Bioengineering (R01EB035545)
- National Nuclear Security Administration (DE-NA0003525)
- National Institutes of Health
- U.S. Department of Energy
- Office of Science
- Los Alamos National Laboratory (89233218CNA000001)
This publication has 58 references indexed in Scilit:
- Intraperitoneal chemotherapy is now back for ovarian cancerInternational Journal of Clinical Oncology, 2025
- Bioactive mesoporous silica materials-assisted cancer immunotherapyBiomaterials, 2024
- Drug delivery methods for cancer immunotherapyDrug Delivery and Translational Research, 2023
- Hollow Aluminum Hydroxide Modified Silica Nanoadjuvants with Amplified Immunotherapy Effects through Immunogenic Cell Death Induction and Antigen ReleaseSmall, 2022
- Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast CancerPharmaceutical Research, 2022
- Mechanisms of immune response to inorganic nanoparticles and their degradation productsAdvanced Drug Delivery Reviews, 2021
- Emerging Lipid-Coated Silica Nanoparticles for Cancer Therapy2021
- Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR deliveryActa Biomaterialia, 2020
- Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodiesWIREs Nanomedicine and Nanobiotechnology, 2020
- Engineering of large-pore lipid-coated mesoporous silica nanoparticles for dual cargo delivery to cancer cellsJournal of Sol-Gel Science and Technology, 2018